NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the “Company”), and a clinical stage, leading global ...

NNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...

NanoViricides, Inc. (NYSE American: NNVC) , a clinical-stage pioneer in host-mimetic nanomedicine, affirmed its preparedness to address the continued ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic ...

NanoViricides, Inc., says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not ...

NanoViricides, Inc., a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities. Anil Diwan, the Company's President, and ...

NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral ...

Press Releases NanoViricides, Inc. Has Filed its Quarterly Report: Broad-Spectrum Antiviral NV-387 To Combat MPox Pandemic in Africa - Phase II Clinical Trial Update, Also Readying to Combat ...

NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral ...

NanoViricides, Inc. (NYSE American.:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, reports today that it has now obtained a right of first ...

NanoViricides Not Affected by Tariffs and Other Policies, Has Excellent Long Term Outlook, Stock-Price Decline Misguided, Explains the Company ...

NanoViricides, Inc. (NYSE American:NNVC) (the “Company”), a clinical stage global leader in broad-spectrum antiviral nanomedicines, is providing an update on its clinical program activities.